Accession Number:



The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment

Descriptive Note:

Technical Report,15 Sep 2015,14 Sep 2016

Corporate Author:

Health Research, Inc., Roswell Park Division Buffalo United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Active surveillance AS is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRBHRPO approval has been obtained for construction and use of new TMAs PI Mohler and Goodrich. The TMAs from PCaP have been obtained PI Mohler and Goodrich. Pathology analysis of 1146 patient specimens is complete and construction of TMAs is complete PI Mohler. Optimization of TMA staining is complete and staining of all TMAs initiated, with staining of some TMAs complete PI Goodrich. IRBHRPO approval for active surveillance specimens has been obtained PI Mohler, Goodrich. Enrollment of prostate cancer patients on active surveillance is ongoing PI Mohler. Developing ELISA assays for measuring pThoc1 and pThoc1 autoantibodies is complete PI Goodrich. IRBHRPO approval for serum samples has been obtained PI Mohler, Goodrich. Analysis of serum samples from human prostate cancer patients has been initiated PI Goodrich. Year 3 of the grant will finish data acquisition and data analysis. Over treatment complicates the clinical management of prostate cancer.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement: